A biotech startup named Vivodyne claims that the current AI drug-discovery field is hampered by a lack of high-quality, human-centric data. Vivodyne has developed modular robotic labs, called HIVE, capable of generating complex human tissue data that can train more accurate AI models. This approach aims to overcome the limitations of current AI models, which often rely on animal testing or simplified biological data, leading to high failure rates in human clinical trials. Vivodyne's system has shown high predictive accuracy compared to human trials and is working with major pharmaceutical companies to improve drug development. AI
IMPACT This approach could accelerate AI-driven drug discovery by providing more accurate and relevant training data, potentially reducing failure rates in clinical trials.
RANK_REASON Startup announces a new approach to data generation for AI drug discovery, addressing a significant industry challenge.
Read on Mastodon — mastodon.social →
- Cancer
- Robot Villas
- TechCrunch
- AlphaFold
- Andrei Georgescu
- Anthropic
- Dario Amodei
- Demis Hassabis
- Google DeepMind
- Isomorphic Labs
- Khosla Ventures
- OpenAI
- Sam Altman
- San Francisco
- University of Pennsylvania
- Vivodyne
- Data
AI-generated summary · Google Gemini · from 6 sources. How we write summaries →
